http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JO-3627-B1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a693232b92910547c898db10feb83fef
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D519-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4985
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-22
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4985
filingDate 2016-04-26-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2020-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4d3819fae7b28b67d3f9b85670dd5f7f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c2e6b0be4f59b1fa2d30e6ff666c51b9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9fbc44074c753a30be1b06a502c0ab2d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6aaf7dc0eaa59d32a9d390269a02a77f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6aa6eb3d971d69ed58a1c529dc0937b6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cf874230780a0cfe3acee9fcda6faca8
publicationDate 2020-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber JO-3627-B1
titleOfInvention imidazopyrazinones as PDE1 inhibitors
abstract The present invention relates to the provision of imidazopyrazinones as a PDE1 inhibitor and its use as a drug, specifically for the treatment of neurodegenerative and psychiatric disorders.
priorityDate 2015-04-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID21140198
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID411299155

Total number of triples: 32.